Loading publications…
The last 5 uploaded publications
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, P. Abada, Masatoshi Kudo (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 20(2), pp. 282-296, DOI: 10.1016/s1470-2045(18)30937-9.
Article145 days agoBrivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul, Éveline Boucher, Masatoshi Kudo, Charissa Chang, Yoon‐Koo Kang, Éric Assenat, Ho-Yeong Lim, Valérie Boige, Philippe Mathurin, Lætitia Fartoux, Deng‐Yn Lin, Jordi Bruix, Ronnie T.P. Poon, Morris Sherman, Jean–Frédéric Blanc, Richard S. Finn, Won Young Tak, Yee Chao, Rana Ezzeddine, David Liu, Ian Walters, Joong‐Won Park (2013). Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. Journal of Clinical Oncology, 31(28), pp. 3509-3516, DOI: 10.1200/jco.2012.47.3009.
Article145 days agoSEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans, Paul J. Ross, Armando Santoro, Flair José Carrilho, Jordi Bruix, Shukui Qin, Paul J. Thuluvath, Josep M. Llovet, Marie-Aude LeBerre, Markus Jensen, Gerold Meinhardt, Yoon‐Koo Kang (2014). SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 33(6), pp. 559-566, DOI: 10.1200/jco.2013.53.7746.
Article145 days agoObjective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Riccardo Lencioni, Robert Montal, Ferrán Torres, Joong‐Won Park, Thomas Decaens, Jean‐Luc Raoul, Masatoshi Kudo, Charissa Chang, José Ríos, Valérie Boige, Éric Assenat, Yoon‐Koo Kang, Ho-Yeong Lim, Ian Walters, Josep M. Llovet (2017). Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. Journal of Hepatology, 66(6), pp. 1166-1172, DOI: 10.1016/j.jhep.2017.01.012.
Article145 days agoFirst-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong‐Won Park, Su Pin Choo, Antoine Hollebecque, Max W. Sung, Ho-Yeong Lim, Vincenzo Mazzaferro, Joerg Trojan, Andrew X. Zhu, Jung‐Hwan Yoon, Sunil Sharma, Zhong-Zhe Lin, Stephen L. Chan, Sandrine Faivre, Lynn G. Feun, Chia-Jui Yen, Jean‐François Dufour, Daniel H. Palmer, Josep M. Llovet, Melissa Manoogian, Meera Tugnait, Nicolas Stransky, Margit Hagel, Nancy E. Kohl, Christoph Lengauer, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Klaus P. Hoeflich, Hongliang Shi, Beni B. Wolf, Yoon‐Koo Kang (2019). First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery, 9(12), pp. 1696-1707, DOI: 10.1158/2159-8290.cd-19-0555.
Article145 days ago